FDA Approves Mounjaro for Cardiovascular Risk Reduction in Type 2 Diabetes

The FDA has approved Mounjaro for cardiovascular risk reduction in people with type 2 diabetes. Milko · E+/Getty The FDA has approved Mounjaro to help reduce the risk of major cardiovascular events in people with type 2 diabetes who are at high risk. A major clinical trial found that Mounjaro performed as well as Trulicity for reducing the risk of heart attack, stroke, and cardiovascular death. People taking Mounjaro had an 8% lower relative risk of major cardiovascular events compared with those taking Trulicity. On August 28, Eli Lilly, the manufacturer of Mounjaro (tirzepatide), announced that the Food and Drug Administration (FDA) approved the GLP-1 medication to help reduce cardiovascular risk in people with type 2 diabetes who are at high risk of cardiovascular events. The recent approval is for the reduction of major adverse cardiovascular events (MACE), which include: non-fatal heart attack non-fatal stroke cardiovascular death “For people with type 2 diabetes, heart disease is the leading cause of death, and Mounjaro … now gives them a proven way to lower that risk, adding to the strong foundation it has already built in A1C and weight,” Kenneth Custer, PhD, executive vic…

≈